

# Maurizio Fava

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4614585/publications.pdf>

Version: 2024-02-01

293  
papers

20,966  
citations

20759

60  
h-index

11899

134  
g-index

297  
all docs

297  
docs citations

297  
times ranked

18335  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. <i>American Journal of Psychiatry</i> , 2006, 163, 28-40.	4.0	3,206
2	Major depressive disorder. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16065.	18.1	1,171
3	Diagnosis and definition of treatment-resistant depression. <i>Biological Psychiatry</i> , 2003, 53, 649-659.	0.7	1,121
4	Harmonization of cortical thickness measurements across scanners and sites. <i>NeuroImage</i> , 2018, 167, 104-120.	2.1	790
5	Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2008, 165, 342-351.	4.0	741
6	DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION. <i>Psychiatric Clinics of North America</i> , 1996, 19, 179-200.	0.7	639
7	The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 156-165.	0.7	478
8	Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. <i>Psychiatric Clinics of North America</i> , 2003, 26, 457-494.	0.7	456
9	Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment. <i>American Journal of Human Genetics</i> , 2006, 78, 804-814.	2.6	434
10	Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder. <i>Biological Psychiatry</i> , 2006, 59, 1052-1060.	0.7	432
11	The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach. <i>Psychotherapy and Psychosomatics</i> , 2003, 72, 115-127.	4.0	407
12	Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 616-630.	1.0	404
13	Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. <i>Psychological Medicine</i> , 2004, 34, 1299-1308.	2.7	352
14	Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. <i>American Journal of Psychiatry</i> , 2016, 173, 575-587.	4.0	315
15	Statistical harmonization corrects site effects in functional connectivity measurements from multi-site fMRI data. <i>Human Brain Mapping</i> , 2018, 39, 4213-4227.	1.9	295
16	Illness Progression, Recent Stress, and Morphometry of Hippocampal Subfields and Medial Prefrontal Cortex in Major Depression. <i>Biological Psychiatry</i> , 2015, 77, 285-294.	0.7	267
17	Folate in Depression. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 12-17.	1.1	256
18	Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches. <i>Biological Psychiatry</i> , 2008, 63, 699-704.	0.7	236

#	ARTICLE	IF	CITATIONS
19	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020, 25, 1592-1603.	4.1	235
20	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. <i>Journal of Psychiatric Research</i> , 2016, 78, 11-23.	1.5	216
21	The Effect of Duloxetine on Painful Physical Symptoms in Depressed Patients. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 521-530.	1.1	182
22	A Cross-Sectional Study of the Prevalence of Cognitive and Physical Symptoms During Long-Term Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1754-1759.	1.1	181
23	Interruption of selective serotonin reuptake inhibitor treatment. <i>British Journal of Psychiatry</i> , 2000, 176, 363-368.	1.7	177
24	A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006, 163, 1161-72.	4.0	167
25	A Multicenter, Placebo-Controlled Study of Modafinil Augmentation in Partial Responders to Selective Serotonin Reuptake Inhibitors With Persistent Fatigue and Sleepiness. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 85-93.	1.1	159
26	An electroencephalographic signature predicts antidepressant response in major depression. <i>Nature Biotechnology</i> , 2020, 38, 439-447.	9.4	157
27	Childhood trauma history is linked to abnormal brain connectivity in major depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8582-8590.	3.3	151
28	What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 823-835.	0.9	148
29	Evaluation of Opioid Modulation in Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 1448-1455.	2.8	143
30	Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice. <i>Psychotherapy and Psychosomatics</i> , 2006, 75, 139-153.	4.0	136
31	Test-retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. <i>Human Brain Mapping</i> , 2015, 36, 3472-3485.	1.9	136
32	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression. <i>JAMA Psychiatry</i> , 2018, 75, 547.	6.0	125
33	A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study). <i>Psychotherapy and Psychosomatics</i> , 2012, 81, 87-97.	4.0	122
34	Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison. <i>Journal of Psychiatric Research</i> , 2017, 87, 61-70.	1.5	122
35	Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. <i>Journal of Affective Disorders</i> , 2019, 243, 516-524.	2.0	120
36	CLINICAL RELEVANCE OF FATIGUE AS A RESIDUAL SYMPTOM IN MAJOR DEPRESSIVE DISORDER. <i>Depression and Anxiety</i> , 2014, 31, 250-257.	2.0	118

#	ARTICLE	IF	CITATIONS
37	An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use. <i>JAMA Psychiatry</i> , 2014, 71, 889.	6.0	118
38	A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 441-447.	0.7	116
39	Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 379-387.	0.7	114
40	Reliability and Validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 91-97.	4.0	114
41	Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. <i>Psychological Medicine</i> , 2019, 49, 1118-1127.	2.7	109
42	Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e719-e725.	1.1	100
43	Guidelines for the recognition and management of mixed depression. <i>CNS Spectrums</i> , 2017, 22, 203-219.	0.7	97
44	Modafinil Augmentation of Selective Serotonin Reuptake Inhibitor Therapy in MDD Partial Responders with Persistent Fatigue and Sleepiness. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 153-159.	0.6	94
45	Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. <i>Psychiatry Journal</i> , 2015, 2015, 1-8.	0.7	90
46	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. <i>American Journal of Psychiatry</i> , 2015, 172, 881-891.	4.0	87
47	Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study. <i>Neuropsychopharmacology</i> , 2016, 41, 454-463.	2.8	84
48	Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 55-64.	1.3	84
49	Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder. <i>Scientific Reports</i> , 2017, 7, 15772.	1.6	83
50	Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 137-147.	0.7	75
51	Somatic Symptoms, Depression, and Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 305-307.	1.1	74
52	Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. <i>Photomedicine and Laser Surgery</i> , 2018, 36, 634-646.	2.1	73
53	Efficacy and Safety of Sildenafil in Men With Serotonergic Antidepressant-Associated Erectile Dysfunction. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 240-246.	1.1	73
54	Efficacy of Esketamine Augmentation in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	71

#	ARTICLE	IF	CITATIONS
55	Serum lipids, recent suicide attempt and recent suicide status in patients with major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 51, 113-118.	2.5	70
56	Improved Insomnia Symptoms and Sleep-Related Next-Day Functioning in Patients With Comorbid Major Depressive Disorder and Insomnia Following Concomitant Zolpidem Extended-Release 12.5 mg and Escitalopram Treatment. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 914-928.	1.1	70
57	Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians. <i>Canadian Journal of Psychiatry</i> , 2000, 45, 476-481.	0.9	69
58	Severe Depression. <i>CNS Drugs</i> , 2001, 15, 765-776.	2.7	69
59	Rare Copy Number Variation in Treatment-Resistant Major Depressive Disorder. <i>Biological Psychiatry</i> , 2014, 76, 536-541.	0.7	67
60	Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 222-230.	0.7	64
61	Understanding the effects of emotional reactivity on depression and suicidal thoughts and behaviors: Moderating effects of childhood adversity and resilience. <i>Journal of Affective Disorders</i> , 2019, 245, 419-427.	2.0	62
62	Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. <i>Neuropsychopharmacology</i> , 2018, 43, 2221-2230.	2.8	61
63	Inflammatory cytokines in major depressive disorder: A case-control study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 23-31.	1.3	60
64	Daytime sleepiness and insomnia as correlates of depression. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 16, 27-32.	1.1	58
65	S-adenosyl methionine (SAME) versus escitalopram and placebo in major depression RCT: Efficacy and effects of histamine and carnitine as moderators of response. <i>Journal of Affective Disorders</i> , 2014, 164, 76-81.	2.0	53
66	Anhedonia in melancholic and non-melancholic depressive disorders. <i>Journal of Affective Disorders</i> , 2015, 184, 81-88.	2.0	53
67	An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): A possible role for neurogenesis in drug discovery. <i>Journal of Psychiatric Research</i> , 2012, 46, 1553-1563.	1.5	52
68	Anger attacks in depression. <i>Depression and Anxiety</i> , 1998, 8, 59-63.	2.0	49
69	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. <i>Biological Psychiatry</i> , 2019, 85, 872-880.	0.7	48
70	The pro-inflammatory profile of depressed patients is (partly) related to obesity. <i>Journal of Psychiatric Research</i> , 2015, 70, 91-97.	1.5	47
71	Paraquat Prohibition and Change in the Suicide Rate and Methods in South Korea. <i>PLoS ONE</i> , 2015, 10, e0128980.	1.1	47
72	Poor sleep quality and suicide attempt among adults with internet addiction: A nationwide community sample of Korea. <i>PLoS ONE</i> , 2017, 12, e0174619.	1.1	47

#	ARTICLE	IF	CITATIONS
73	Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. <i>Molecular Psychiatry</i> , 2020, 25, 1580-1591.	4.1	46
74	Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. <i>Psychoneuroendocrinology</i> , 2015, 58, 9-22.	1.3	45
75	Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2020, 77, 397.	6.0	45
76	REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 122-131.	4.0	44
77	Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. <i>Journal of Affective Disorders</i> , 2014, 168, 439-451.	2.0	43
78	Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. <i>American Journal of Psychiatry</i> , 2015, 172, 1251-1258.	4.0	43
79	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. <i>Depression and Anxiety</i> , 2016, 33, 56-65.	2.0	43
80	A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. <i>Statistics in Medicine</i> , 2013, 32, 2767-2789.	0.8	42
81	S-Adenosylmethionine (Ademetionine) in Psychiatric Disorders. <i>CNS Drugs</i> , 1996, 6, 416-425.	2.7	41
82	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. <i>Journal of Psychiatric Research</i> , 2019, 110, 166-171.	1.5	41
83	Treatment Approaches to Major Depressive Disorder Relapse. <i>Psychotherapy and Psychosomatics</i> , 2002, 71, 195-199.	4.0	40
84	Feelings of worthlessness, traumatic experience, and their comorbidity in relation to lifetime suicide attempt in community adults with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 206-212.	2.0	40
85	Pharmacological approaches to the treatment of residual symptoms. <i>Journal of Psychopharmacology</i> , 2006, 20, 29-34.	2.0	39
86	Web-Based Depression Screening and Psychiatric Consultation for College Students: A Feasibility and Acceptability Study. <i>International Journal of Telemedicine and Applications</i> , 2014, 2014, 1-9.	1.1	39
87	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 285-295.	4.0	39
88	Efficacy of adjunctive low-dose cariprazine in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2018, 33, 312-321.	0.9	37
89	Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 164, 102219.	1.0	37
90	Redefining Affective Disorders: Relevance for Drug Development. <i>CNS Neuroscience and Therapeutics</i> , 2008, 14, 2-9.	1.9	37

#	ARTICLE	IF	CITATIONS
91	Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the Research Domain Criteria (RDoC). <i>Journal of Affective Disorders</i> , 2014, 163, 18-24.	2.0	36
92	A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2017, 42, 2567-2574.	2.8	36
93	Development and validation study of the Smartphone Overuse Screening Questionnaire. <i>Psychiatry Research</i> , 2017, 257, 352-357.	1.7	36
94	Illness beliefs of Chinese American immigrants with major depressive disorder in a primary care setting. <i>Asian Journal of Psychiatry</i> , 2015, 13, 16-22.	0.9	35
95	Increased adrenocorticotrophic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder. <i>Psychiatry Research</i> , 2018, 270, 246-252.	1.7	35
96	Development and evaluation of a multimodal marker of major depressive disorder. <i>Human Brain Mapping</i> , 2018, 39, 4420-4439.	1.9	35
97	THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS'S PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. <i>Depression and Anxiety</i> , 2015, 32, 605-613.	2.0	34
98	A Post Hoc Analysis of the Effect of Nightly Administration of Eszopiclone and a Selective Serotonin Reuptake Inhibitor in Patients With Insomnia and Anxious Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 473-479.	1.1	34
99	Prospective association between major depressive disorder and leukocyte telomere length over two years. <i>Psychoneuroendocrinology</i> , 2018, 90, 157-164.	1.3	32
100	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	32
101	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 483-494.	1.3	32
102	A Double-Blind Placebo-Controlled Trial of Maca Root as Treatment for Antidepressant-Induced Sexual Dysfunction in Women. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-9.	0.5	30
103	A comparison of structural connectivity in anxious depression versus non-anxious depression. <i>Journal of Psychiatric Research</i> , 2017, 89, 38-47.	1.5	30
104	A Pilot, Randomized Controlled Study of Tai Chi With Passive and Active Controls in the Treatment of Depressed Chinese Americans. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e522-e528.	1.1	30
105	Switching to Reboxetine: An Efficacy and Safety Study in Patients With Major Depressive Disorder Unresponsive to Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 365-369.	0.7	29
106	Brain regulation of emotional conflict predicts antidepressant treatment response for depression. <i>Nature Human Behaviour</i> , 2019, 3, 1319-1331.	6.2	29
107	Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. <i>Molecular Psychiatry</i> , 2020, 25, 1526-1536.	4.1	29
108	Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses. <i>Current Therapeutic Research</i> , 2005, 66, 522-540.	0.5	28

#	ARTICLE	IF	CITATIONS
109	Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study. <i>Advances in Therapy</i> , 2017, 34, 524-541.	1.3	28
110	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. <i>Magnetic Resonance Imaging</i> , 2018, 45, 26-33.	1.0	28
111	Discovery and replication of cerebral blood flow differences in major depressive disorder. <i>Molecular Psychiatry</i> , 2020, 25, 1500-1510.	4.1	28
112	Management of depression relapse: Re-initiation of duloxetine treatment or dose increase. <i>Journal of Psychiatric Research</i> , 2006, 40, 328-336.	1.5	27
113	Reliability and validity of the Symptoms of Depression Questionnaire (SDQ). <i>CNS Spectrums</i> , 2014, 19, 535-546.	0.7	27
114	Online recovery support meetings can help mitigate the public health consequences of COVID-19 for individuals with substance use disorder. <i>Addictive Behaviors</i> , 2021, 113, 106661.	1.7	27
115	Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2015, 187, 183-187.	2.0	26
116	The promise and challenges of drug repurposing in psychiatry. <i>World Psychiatry</i> , 2018, 17, 28-29.	4.8	26
117	Massachusetts General Hospital SAFER Criteria for Clinical Trials and Research. <i>Harvard Review of Psychiatry</i> , 2013, 21, 269-274.	0.9	25
118	Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression. <i>Clinical EEG and Neuroscience</i> , 2019, 50, 3-12.	0.9	25
119	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 287-292.	0.7	25
120	Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	25
121	Reward Responsiveness Varies by Smoking Status in Women with a History of Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 1940-1946.	2.8	24
122	From depression to anxiety, and back. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 341-342.	2.2	24
123	Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. <i>Journal of Affective Disorders</i> , 2019, 246, 157-165.	2.0	24
124	Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder. <i>Journal of Psychiatric Research</i> , 2015, 68, 392-396.	1.5	23
125	Linking major depression and the neural substrates of associative processing. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2016, 16, 1017-1026.	1.0	23
126	A Randomized Controlled Pilot Study on Mindfulness-Based Cognitive Therapy for Unipolar Depression in Patients With Chronic Pain. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 26-34.	1.1	23



#	ARTICLE	IF	CITATIONS
127	Tachyphylaxis in major depressive disorder: A review of the current state of research. <i>Journal of Affective Disorders</i> , 2019, 245, 488-497.	2.0	23
128	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. <i>Biological Psychiatry</i> , 2020, 88, 657-667.	0.7	23
129	Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study. <i>Journal of Psychiatric Research</i> , 2021, 133, 73-81.	1.5	23
130	The Effectiveness of Telepsychiatry-Based Culturally Sensitive Collaborative Treatment for Depressed Chinese American Immigrants. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e996-e1002.	1.1	23
131	The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 187-195.	0.6	22
132	Antidepressant-like effect of low dose ketamine and scopolamine co-treatment in mice. <i>Neuroscience Letters</i> , 2016, 620, 70-73.	1.0	22
133	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj 5 6, 22-30.	0.5	22
134	Alcohol-induced disinhibition is associated with impulsivity, depression, and suicide attempt: A nationwide community sample of Korean adults. <i>Journal of Affective Disorders</i> , 2018, 227, 323-329.	2.0	22
135	Sexual functioning and SSRIs. <i>Journal of Clinical Psychiatry</i> , 2002, 63 Suppl 5, 13-6; discussion 23-5.	1.1	22
136	Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2009, 113, 263-271.	2.0	21
137	Anterior insula activation during inhibition to smoking cues is associated with ability to maintain tobacco abstinence. <i>Addictive Behaviors Reports</i> , 2018, 7, 40-46.	1.0	21
138	A randomized controlled dosing study of Iyengar yoga and coherent breathing for the treatment of major depressive disorder: Impact on suicidal ideation and safety findings. <i>Complementary Therapies in Medicine</i> , 2018, 37, 136-142.	1.3	21
139	Anxiety Symptoms Questionnaire (ASQ): development and validation. <i>Annals of General Psychiatry</i> , 2019, 32, e100144.	1.1	21
140	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020, 260, 131-139.	2.0	21
141	Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 169, 112-117.	2.0	20
142	Obsessive-Compulsive Symptoms as a Risk Factor for Suicidality in U.S. College Students. <i>Journal of Adolescent Health</i> , 2016, 58, 481-484.	1.2	20
143	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , 2018, 11, 75-84.	0.7	20
144	Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study. <i>PLoS ONE</i> , 2015, 10, e0126326.	1.1	20

#	ARTICLE	IF	CITATIONS
145	The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 13, 26-9.	1.1	20
146	Metabolic Assessment of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 362-367.	0.7	19
147	Gender Differences in Somatic Symptoms and Current Suicidal Risk in Outpatients with Major Depressive Disorder. <i>Psychiatry Investigation</i> , 2016, 13, 609.	0.7	19
148	Outcomes of an online computerized cognitive behavioral treatment program for treating chinese patients with depression: A pilot study. <i>Asian Journal of Psychiatry</i> , 2018, 38, 102-107.	0.9	19
149	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. <i>EClinicalMedicine</i> , 2019, 10, 32-41.	3.2	19
150	Effect of Korean Red Ginseng in individuals exposed to high stress levels: a 6-week, double-blind, randomized, placebo-controlled trial. <i>Journal of Ginseng Research</i> , 2019, 43, 402-407.	3.0	19
151	Association Between Stigma and Depression Outcomes Among Chinese Immigrants in a Primary Care Setting. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1287-e1292.	1.1	19
152	A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders. <i>primary care companion for CNS disorders</i> , The, 2015, 17, .	0.2	19
153	Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression. <i>Frontiers in Psychiatry</i> , 2018, 9, 424.	1.3	18
154	Increased Morbidity of Major Depressive Disorder After Thyroidectomy: A Nationwide Population-Based Study in South Korea. <i>Thyroid</i> , 2019, 29, 1713-1722.	2.4	18
155	Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 691.	6.0	18
156	Effects of transcranial photobiomodulation with near-infrared light on sexual dysfunction. <i>Lasers in Surgery and Medicine</i> , 2019, 51, 127-135.	1.1	18
157	Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. <i>Journal of Affective Disorders</i> , 2020, 276, 660-666.	2.0	18
158	John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials. <i>Pain</i> , 2020, 161, S3-S13.	2.0	18
159	Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1695-1701.	1.1	18
160	Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder. <i>Psychiatry Investigation</i> , 2016, 13, 321.	0.7	18
161	Screening for Suicide Risk in the College Population. <i>Journal of Rational - Emotive and Cognitive - Behavior Therapy</i> , 2015, 33, 78-94.	1.0	17
162	Relationship between placebo response rate and clinical trial outcome in bipolar depression. <i>Journal of Psychiatric Research</i> , 2016, 74, 38-44.	1.5	17

#	ARTICLE	IF	CITATIONS
163	Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings From the EMBARC Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 138-148.	1.1	17
164	Cortical thickness is not associated with current depression in a clinical treatment study. <i>Human Brain Mapping</i> , 2017, 38, 4370-4385.	1.9	17
165	Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder. <i>Scientific Reports</i> , 2019, 9, 7462.	1.6	17
166	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. <i>Journal of Affective Disorders</i> , 2019, 245, 1070-1078.	2.0	17
167	Genetic Association of Attention-Deficit/Hyperactivity Disorder and Major Depression With Suicidal Ideation and Attempts in Children: The Adolescent Brain Cognitive Development Study. <i>Biological Psychiatry</i> , 2022, 92, 236-245.	0.7	17
168	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Augmentation of a Nicotinic Acetylcholine Receptor Partial Agonist in Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 51-56.	0.7	16
169	Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive disorder: A three week double blind pilot study. <i>Journal of Psychiatric Research</i> , 2015, 70, 98-105.	1.5	16
170	Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2019, 258, 102-108.	2.0	16
171	The Engagement Interview Protocol (EIP): improving the acceptance of mental health treatment among Chinese immigrants. <i>International Journal of Culture and Mental Health</i> , 2011, 4, 91-105.	0.6	15
172	Placebo non-response measure in sequential parallel comparison design studies. <i>Statistics in Medicine</i> , 2015, 34, 2281-2293.	0.8	15
173	Celebrity Suicides and Their Differential Influence on Suicides in the General Population: A National Population-Based Study in Korea. <i>Psychiatry Investigation</i> , 2015, 12, 204.	0.7	15
174	Association between physician beliefs regarding assigned treatment and clinical response: Re-analysis of data from the Hypericum Depression Trial Study Group. <i>Asian Journal of Psychiatry</i> , 2015, 13, 23-29.	0.9	15
175	Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning. <i>International Journal of Neuropsychopharmacology</i> , 2016, 20, pyw087.	1.0	15
176	Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. <i>Neuropsychopharmacology</i> , 2019, 44, 2268-2276.	2.8	15
177	Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. <i>Journal of Psychopharmacology</i> , 2019, 33, 511-521.	2.0	15
178	Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2020, 128, 43-51.	1.5	15
179	Altered temporal, but intact spatial, features of transient network dynamics in psychosis. <i>Molecular Psychiatry</i> , 2021, 26, 2493-2503.	4.1	15
180	Switching to bupropion in fluoxetine-resistant major depressive disorder. <i>Annals of Clinical Psychiatry</i> , 2003, 15, 17-22.	0.6	15

#	ARTICLE	IF	CITATIONS
181	Risks of Completed Suicide of Community Individuals with ICD-10 Disorders Across Age Groups: A Nationwide Population-Based Nested Case-Control Study in South Korea. <i>Psychiatry Investigation</i> , 2019, 16, 314-324.	0.7	15
182	Effects of Adjunctive Aripiprazole on Sexual Functioning in Patients With Major Depressive Disorder and an Inadequate Response to Standard Antidepressant Monotherapy. <i>primary care companion for CNS disorders</i> , The, 2011, 13, .	0.2	15
183	Sleep Quality, Posttraumatic Stress, Depression, and Human Errors in Train Drivers: A Population-Based Nationwide Study in South Korea. <i>Sleep</i> , 2014, 37, 1969-1975.	0.6	14
184	Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 428-433.	0.7	14
185	Prolactin and stress. <i>Stress and Health</i> , 1987, 3, 211-216.	0.7	13
186	The Effects of Tai Chi on Sleep Quality in Chinese American Patients With Major Depressive Disorder: A Pilot Study. <i>Behavioral Sleep Medicine</i> , 2018, 16, 398-411.	1.1	13
187	Binge eating, trauma, and suicide attempt in community adults with major depressive disorder. <i>PLoS ONE</i> , 2018, 13, e0198192.	1.1	13
188	Predictive factors of diagnostic conversion from major depressive disorder to bipolar disorder in young adults ages 19â€”34: A nationwide population study in South Korea. <i>Journal of Affective Disorders</i> , 2020, 265, 52-58.	2.0	13
189	Risk Factors for Depression in Adolescents With ADHD: The Impact of Cognitive Biases and Stress. <i>Journal of Attention Disorders</i> , 2021, 25, 340-354.	1.5	13
190	Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2015, 72, 1073.	6.0	12
191	Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2018, 102, 207-215.	1.5	12
192	Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response. <i>Journal of Affective Disorders</i> , 2019, 256, 8-16.	2.0	12
193	Increased amygdala-visual cortex connectivity in youth with persecutory ideation. <i>Psychological Medicine</i> , 2020, 50, 273-283.	2.7	12
194	Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extendedâ€”Release and Longâ€”Acting Injectable Paliperidone. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1296-1306.	1.0	11
195	Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study. <i>Comprehensive Psychiatry</i> , 2019, 95, 152140.	1.5	11
196	Risks of suicide attempts after prescription of zolpidem in people with depression: a nationwide population study in South Korea. <i>Sleep</i> , 2020, 43, .	0.6	11
197	Anxious attachment is associated with heightened responsivity of a parietofrontal cortical network that monitors peri-personal space. <i>NeuroImage: Clinical</i> , 2021, 30, 102585.	1.4	11
198	Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	11

#	ARTICLE	IF	CITATIONS
199	Effectiveness of the Relaxation Response-Based Group Intervention for Treating Depressed Chinese American Immigrants: A Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 9186-9201.	1.2	10
200	Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study. <i>Journal of Affective Disorders</i> , 2015, 185, 24-30.	2.0	10
201	Lifetime suicidal ideation and attempt in adults with full major depressive disorder versus sustained depressed mood. <i>Journal of Affective Disorders</i> , 2016, 203, 275-280.	2.0	10
202	Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. <i>CNS Spectrums</i> , 2017, 22, 228-235.	0.7	10
203	Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 276-278.	0.7	10
204	Launching a resiliency group program to assist frontline clinicians in meeting the challenges of the COVID-19 pandemic: Results of a hospital-based systems trial. <i>General Hospital Psychiatry</i> , 2021, 68, 111-112.	1.2	10
205	Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 314-326.	0.7	10
206	A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. <i>Journal of Affective Disorders</i> , 2022, 296, 549-558.	2.0	10
207	Augmenting antidepressants with folate: a clinical perspective. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 10, 4-7.	1.1	10
208	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 956-967.	1.3	9
209	Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients. <i>European Neuropsychopharmacology</i> , 2014, 24, 1188-1195.	0.3	9
210	Community-Delivered Heated Hatha Yoga as a Treatment for Depressive Symptoms: An Uncontrolled Pilot Study. <i>Journal of Alternative and Complementary Medicine</i> , 2019, 25, 814-823.	2.1	9
211	Can electronic health records revive central nervous system clinical trials?. <i>Molecular Psychiatry</i> , 2019, 24, 1096-1098.	4.1	9
212	Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review. <i>Molecular Psychiatry</i> , 2020, 25, 1967-1974.	4.1	9
213	Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial. <i>Biological Psychiatry</i> , 2022, 91, 550-560.	0.7	9
214	Association of smartphone overuse with depression, anxiety, and other addictive behaviors: A nationwide community sample of Korean adults. <i>Psychiatry Research</i> , 2021, 304, 114133.	1.7	9
215	Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 449-455.	1.1	9
216	Review of Suicide Prevention Programs: Massachusetts, United States, in Comparison with Seoul. <i>Psychiatry Investigation</i> , 2015, 12, 281.	0.7	9

#	ARTICLE	IF	CITATIONS
217	Prospective studies of adverse events related to antidepressant discontinuation. <i>Journal of Clinical Psychiatry</i> , 2006, 67 Suppl 4, 14-21.	1.1	9
218	Sex Differences in the Association between Heavy Drinking and Behavioral Distress Tolerance and Emotional Reactivity Among Non-Depressed College Students. <i>Alcohol and Alcoholism</i> , 2018, 53, 674-681.	0.9	8
219	Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 262, 118-125.	2.0	8
220	Elevated Amygdala Activity in Young Adults With Familial Risk for Depression: A Potential Marker of Low Resilience. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 194-202.	1.1	8
221	All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment. <i>American Journal of Psychiatry</i> , 2020, 177, 173-174.	4.0	8
222	Relationship between cannabis use and psychotic experiences in college students. <i>Schizophrenia Research</i> , 2021, 231, 198-204.	1.1	8
223	Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. , 2020, 33, 18-26.		8
224	Are Dependency and Self-Criticism Risk Factors for Major Depressive Disorder?. <i>Canadian Journal of Psychiatry</i> , 1997, 42, 291-297.	0.9	7
225	A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo Response. <i>Neuropsychopharmacology</i> , 2015, 40, 2588-2595.	2.8	7
226	Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. <i>Journal of Affective Disorders</i> , 2019, 259, 349-354.	2.0	7
227	Multiple types of somatic pain increase suicide attempts and depression: A nationwide community sample of Korean adults. <i>Comprehensive Psychiatry</i> , 2019, 90, 43-48.	1.5	7
228	Paranoid Ideation Without Psychosis Is Associated With Depression, Anxiety, and Suicide Attempts in General Population. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 826-831.	0.5	7
229	Association of anger attacks with suicidal ideation in adults with major depressive disorder: Findings from the EMBARC study. <i>Depression and Anxiety</i> , 2021, 38, 57-66.	2.0	7
230	Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention deficit/hyperactivity disorder. <i>International Journal of Clinical Practice</i> , 2021, 75, e14330.	0.8	7
231	Increased metabolic variability is associated with newly diagnosed depression: A nationwide cohort study. <i>Journal of Affective Disorders</i> , 2021, 294, 786-793.	2.0	7
232	Comparisons of Subthreshold Versus Full Posttraumatic Stress Disorder Distinguished by Subjective Functional Impairment Among Train Drivers: A Population-Based Nationwide Study in South Korea. <i>Psychiatry Investigation</i> , 2017, 14, 1.	0.7	7
233	Comparison of suicide attempts in individuals with major depressive disorder with and without history of subthreshold hypomania: A nationwide community sample of Korean adults. <i>Journal of Affective Disorders</i> , 2019, 248, 18-25.	2.0	6
234	Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. <i>Psychological Medicine</i> , 2022, 52, 2441-2449.	2.7	6

#	ARTICLE	IF	CITATIONS
235	Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study. <i>Psychological Medicine</i> , 2020, , 1-9.	2.7	6
236	Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 20-28.	1.1	6
237	Anger attacks in depression. <i>Depression and Anxiety</i> , 1998, 8, 59-63.	2.0	6
238	Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 55-59.	1.1	6
239	Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 82, .	1.1	6
240	Transitioning From In-Person to Remote Clinical Research on Depression and Traumatic Brain Injury During the COVID-19 Pandemic: Study Modifications and Preliminary Feasibility From a Randomized Controlled Pilot Study. <i>JMIR Formative Research</i> , 2021, 5, e28734.	0.7	6
241	Depression with physical symptoms: treating to remission. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 7, 24-8.	1.1	6
242	What is the overlap between subjective and objective cognitive impairments in MDD?. <i>Annals of Clinical Psychiatry</i> , 2018, 30, 176-184.	0.6	6
243	High Bodyweight Variability Increases Depression Risk in Patients With Type 2 Diabetes Mellitus: A Nationwide Cohort Study in Korea. <i>Frontiers in Psychiatry</i> , 2021, 12, 765129.	1.3	6
244	Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. <i>Journal of Psychiatric Research</i> , 2015, 62, 56-61.	1.5	5
245	Loss of sexual interest and premenstrual mood change in women with postpartum versus non-postpartum depression: A nationwide community sample of Korean adults. <i>Journal of Affective Disorders</i> , 2016, 191, 222-229.	2.0	5
246	Anxiety attacks with or without life-threatening situations, major depressive disorder, and suicide attempt: a nationwide community sample of Korean adults. <i>Psychiatry Research</i> , 2018, 270, 257-263.	1.7	5
247	Model-Informed Approach to Assess the Treatment Effect Conditional to the Level of Placebo Response. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1253-1260.	2.3	5
248	Design and Methods of the Korean National Investigations of 70,000 Suicide Victims Through Police Records (The KNIGHTS Study). <i>Psychiatry Investigation</i> , 2019, 16, 777-788.	0.7	5
249	A Cross-Sectional Study of Private Psychiatric Practices under a Single-Payer Health Care System. <i>Canadian Journal of Psychiatry</i> , 1997, 42, 395-401.	0.9	4
250	Cross-national differences in hypochondriasis symptoms between Korean and American outpatients with major depressive disorder. <i>Psychiatry Research</i> , 2016, 245, 127-132.	1.7	4
251	Does folic acid interfere with lamotrigine?. <i>Lancet Psychiatry</i> , the, 2016, 3, 704-705.	3.7	4
252	Placebo Response as a Latent Characteristic: Application to Analysis of Sequential Parallel Comparison Design Studies. <i>Journal of the American Statistical Association</i> , 2018, 113, 1411-1430.	1.8	4

#	ARTICLE	IF	CITATIONS
253	Optimal dosing of antidepressant drugs. <i>Lancet Psychiatry</i> , 2019, 6, 805-806.	3.7	4
254	A commentary on: statistical inference problems in sequential parallel comparison designs. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 1130-1133.	0.4	4
255	Moderators of a resiliency group intervention for frontline clinicians during the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2021, 293, 373-378.	2.0	4
256	Bullying, Psychological, and Physical Trauma During Early Life Increase Risk of Major Depressive Disorder in Adulthood: A Nationwide Community Sample of Korean Adults. <i>Frontiers in Psychiatry</i> , 2022, 13, 792734.	1.3	4
257	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2022, 149, 243-251.	1.5	4
258	A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 4-12.	1.2	3
259	The Impact of Childhood Trauma, Hallucinations, and Emotional Reactivity on Delusional Ideation. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	3
260	Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2021, 282, 602-610.	2.0	3
261	Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 317-323.	1.1	3
262	Is It Time to Try Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Again?. <i>JAMA Psychiatry</i> , 2022, , .	6.0	3
263	A Phase 2a Double-Blind Randomized Trial of REL-1017 (Esmethadone) in Patients with MDD: Analysis of Subscales from the Symptoms of Depression Questionnaire. <i>CNS Spectrums</i> , 2022, 27, 235-235.	0.7	3
264	Fatigue across the CNS spectrum: a clinical review. <i>Fatigue: Biomedicine, Health and Behavior</i> , 2014, 2, 231-246.	1.2	2
265	Lessons Learned From the VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) Study. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 126.	3.8	2
266	114 An Assessment of QTc Effects With SPN-812 (Extended-Release Viloxazine) in Healthy Adults. <i>CNS Spectrums</i> , 2020, 25, 274-274.	0.7	2
267	Obsessive Thought, Compulsive Behavior, and Their Associations With Suicide Ideation and Attempts and Major Depressive Disorder. <i>Journal of Nervous and Mental Disease</i> , 2021, Publish Ahead of Print, 820-828.	0.5	2
268	Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. <i>Psychiatry Investigation</i> , 2017, 14, 491.	0.7	2
269	High body weight variability is associated with increased risk of depression: a nationwide cohort study in South Korea. <i>Psychological Medicine</i> , 2022, , 1-9.	2.7	2
270	The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention deficit/hyperactivity disorder. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4828-4838.	1.1	2



#	ARTICLE	IF	CITATIONS
271	Major depressive disorder with psychosis-like symptoms in Latinos: treatment with and without antipsychotic augmentation. <i>International Journal of Culture and Mental Health</i> , 2015, 8, 137-149.	0.6	1
272	PET imaging of neurotransmission using direct parametric reconstruction. <i>NeuroImage</i> , 2020, 221, 117154.	2.1	1
273	Comparisons Between Successful Versus Unsuccessful Switches From Benzodiazepines or Zolpidem (Z-Drug) to Controlled-Release Melatonin in Patients With Major Depressive Disorder and Insomnia. <i>Frontiers in Psychiatry</i> , 2020, 11, 444.	1.3	1
274	Suppression and acceptance in unipolar depression: Short-term and long-term effects on emotional responding. <i>British Journal of Clinical Psychology</i> , 2021, , .	1.7	1
275	Augmentation and combination strategies to treat the residual symptoms of major depressive disorder. <i>Psychiatry</i> , 2007, 4, 16-8.	0.3	1
276	OUP accepted manuscript. <i>Brain</i> , 2022, , .	3.7	1
277	Cultivating social support: the role of peer support in self-management. , 0, , 163-189.		0
278	Self-management of depression using meditation. , 0, , 138-162.		0
279	Using the Electronic Medical Record to Examine Racial and Ethnic Differences in Depression Diagnosis and Treatment in a Primary Care Population. <i>Primary Health Care: Open Access</i> , 2011, 01, 1000106.	0.0	0
280	[P4â€“543]: COGNITIVE FUNCTION AS A PROXY OF FINANCIAL DECISION MAKING IN OLDER PRIMARY CARE ADULTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1558.	0.4	0
281	Is It Time for Going Beyond the <i>P</i> -Value Paradigm With the Estimation of the Probability of Clinical Benefit as a Criterion for Assessing the Outcomes of a Clinical Trial? A Case Study in Patients With Major Depressive Disorder. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 740-749.	1.0	0
282	F27. EFFICACY OF MONTHLY EXTENDED-RELEASE RISPERIDONE INJECTIONS (RBP-7000) FOR THE TREATMENT OF SCHIZOPHRENIA: AN ANALYSIS OF INDIVIDUAL PANSS ITEMS. <i>Schizophrenia Bulletin</i> , 2019, 45, S264-S265.	2.3	0
283	3.4 CHANGES IN AMYGDALA AND HIPPOCAMPAL FUNCTIONAL CONNECTIVITY IN SUBCLINICAL PSYCHOSIS: RELATIONSHIP TO SYMPTOM PERSISTENCE, PARANOIA AND ABERRANT SALIENCE. <i>Schizophrenia Bulletin</i> , 2019, 45, S90-S91.	2.3	0
284	Dose-Dependent Effects of EPA Supplementation on Plasma Specialized Pro-Resolving Mediators in Major Depressive Disorder Patients with Chronic Inflammation. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa068_023.	0.1	0
285	Increased risk of depression before and after unilateral or bilateral oophorectomy: A self-controlled case series study using a nationwide cohort in South Korea. <i>Journal of Affective Disorders</i> , 2021, 285, 47-54.	2.0	0
286	A Patient with Treatment-resistant Depression Who Achieved Remission with Heated Yoga: A Case Report. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , 2021, 12, 12-17.	0.3	0
287	The use of self-management for depression. , 0, , 1-23.		0
288	Care management of depression: treatment of depression in primary care and the need for a multidisciplinary approach. , 0, , 24-45.		0

#	ARTICLE	IF	CITATIONS
289	Self-assessment instruments for depression. , 2009, , 46-67.		0
290	Self-help: the role of bibliotherapy and computerized psychotherapy in self-management for depression. , 0, , 68-106.		0
291	Physical exercise as a form of self-management for depression. , 0, , 107-137.		0
292	Putting it all together: applying self-management for depression in your practice. , 0, , 190-198.		0
293	Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder. CNS Spectrums, 2022, 27, 236-236.	0.7	0